Recent Advances in Ocular Graft-versus-host Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 10

PMID 36761771

Authors

Xianjing Cheng

Ruihao Huang

Shiqin Huang

Wei Fan

Rongdi Yuan

Xiaoqi Wang

Xi Zhang

Affiliations

Soon will be listed here.

Abstract

Ocular graft-versus-host-disease (GVHD) remains a significant clinical complication after allogeneic hematopoietic stem cell transplantation. Impaired visual function, pain, and other symptoms severely affect affected individuals' quality of life. However, the diagnosis of and therapy for ocular GVHD involve a multidisciplinary approach and remain challenging for both hematologists and ophthalmologists, as there are no unified international criteria. Through an exploration of the complex pathogenesis of ocular GVHD, this review comprehensively summarizes the pathogenic mechanism, related tear biomarkers, and clinical characteristics of this disease. Novel therapies based on the mechanisms are also discussed to provide insights into the ocular GVHD treatment.

Citing Articles

Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.

Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K Clin Hematol Int. 2024; 6(4):74-88.

PMID: 39469117 PMC: 11514143. DOI: 10.46989/001c.124926.

Umbilical Cord Blood Platelet Lysate Eyedrops for the Treatment of Severe Ocular Surface Disorders in Graft vs. Host Disease Patients: Clinical Study.

Gagliano C, Foti R, Zeppieri M, Maniaci A, Lavalle S, Tancredi G Life (Basel). 2024; 14(10).

PMID: 39459568 PMC: 11509496. DOI: 10.3390/life14101268.

Chronic Ocular GVHD Treatment at Two Locations of a Tertiary Referral Center.

Qureshi M, Garcia J, Quillen J, Mead-Harvey C, Wentz C, Nau C Clin Ophthalmol. 2024; 18:2731-2739.

PMID: 39372222 PMC: 11451401. DOI: 10.2147/OPTH.S463526.

Ocular tear fluid biomarkers collected by contact lenses.

Boychev N, Yeung V, Yang M, Kanu L, Ross A, Kuang L Biochem Biophys Res Commun. 2024; 734:150744.

PMID: 39340927 PMC: 11586051. DOI: 10.1016/j.bbrc.2024.150744.

Safety and efficacy of human amniotic epithelial stem cell eye drops in ocular chronic graft--host disease.

Cheng X, Fan W, Huang R, Zhao Y, Tang Y, Huang S Haematologica. 2024; 110(2):470-474.

PMID: 39323415 PMC: 11788612. DOI: 10.3324/haematol.2023.284571.

References

Riemens A, Stoyanova E, Rothova A, Kuiper J . Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. Mol Vis. 2012; 18:797-802. PMC: 3324363. View

Mukai S, Ogawa Y, Urano F, Kudo-Saito C, Kawakami Y, Tsubota K . Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid. Sci Rep. 2017; 7:41939. PMC: 5292729. DOI: 10.1038/srep41939. View

Behrendorff N, Dolai S, Hong W, Gaisano H, Thorn P . Vesicle-associated membrane protein 8 (VAMP8) is a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) selectively required for sequential granule-to-granule fusion. J Biol Chem. 2011; 286(34):29627-34. PMC: 3283193. DOI: 10.1074/jbc.M111.265199. View

Westekemper H, Scholz S, Thomasen H, Halfwassen C, Steuhl K . [Ocular graft versus host disease : Corneal complications]. Ophthalmologe. 2017; 114(8):697-702. DOI: 10.1007/s00347-017-0488-9. View

Tovar A, White I, Sabater A . Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases. Medicines (Basel). 2021; 8(2). PMC: 7916115. DOI: 10.3390/medicines8020012. View

Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A . Proposed diagnostic criteria for seborrheic meibomian gland dysfunction. Cornea. 2010; 29(9):980-4. DOI: 10.1097/ICO.0b013e3181cc7b1b. View

Royer D, Echegaray-Mendez J, Lin L, Gmyrek G, Mathew R, Saban D . Complement and CD4 T cells drive context-specific corneal sensory neuropathy. Elife. 2019; 8. PMC: 6783265. DOI: 10.7554/eLife.48378. View

Pathak M, Diep P, Lai X, Brinch L, Ruud E, Drolsum L . Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. Bone Marrow Transplant. 2018; 53(7):863-872. PMC: 6039390. DOI: 10.1038/s41409-018-0090-z. View

An S, Raju I, Surenkhuu B, Kwon J, Gulati S, Karaman M . Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. Ocul Surf. 2019; 17(3):589-614. PMC: 6721977. DOI: 10.1016/j.jtos.2019.03.010. View

10.

Ma J, Li C, Zhao Y, Shen Z, Hu B, Peng R . Ophthalmic manifestations are associated with reduced tear lymphotoxin-α levels in chronic ocular graft-versus-host disease. BMC Ophthalmol. 2022; 22(1):18. PMC: 8751380. DOI: 10.1186/s12886-022-02251-y. View

11.

Hwang H, Ha M, Kim H, Na K . Longitudinal analysis of meibomian gland dropout in patients with ocular graft-versus-host disease. Ocul Surf. 2019; 17(3):464-469. DOI: 10.1016/j.jtos.2019.04.009. View

12.

Bonelli F, Lasagni Vitar R, Merlo Pich F, Fonteyne P, Rama P, Mondino A . Corneal endothelial cell reduction and increased Neurokinin-1 receptor expression in a graft-versus-host disease preclinical model. Exp Eye Res. 2022; 220:109128. DOI: 10.1016/j.exer.2022.109128. View

13.

Ogawa Y, Kawakami Y, Tsubota K . Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease. Int J Mol Sci. 2021; 22(11). PMC: 8201206. DOI: 10.3390/ijms22116114. View

14.

Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M . Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999; 83(10):1125-30. PMC: 1722843. DOI: 10.1136/bjo.83.10.1125. View

15.

Ikarashi H, Aketa N, Shimizu E, Takano Y, Kawakita T, Uchino Y . Two case reports of continued progression of chronic ocular graft-versus-host disease without concurrent systemic comorbidities treated by amniotic membrane transplantation. BMC Ophthalmol. 2021; 21(1):164. PMC: 8028795. DOI: 10.1186/s12886-021-01925-3. View

16.

Tahmaz V, Gehlsen U, Sauerbier L, Holtick U, Engel L, Radojska S . Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br J Ophthalmol. 2016; 101(3):322-326. DOI: 10.1136/bjophthalmol-2015-307666. View

17.

Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito M, Fujita S . Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol. 2002; 170(1):588-96. DOI: 10.4049/jimmunol.170.1.588. View

18.

Mun C, Gulati S, Tibrewal S, Chen Y, An S, Surenkhuu B . A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease. Transl Vis Sci Technol. 2019; 8(3):10. PMC: 6504128. DOI: 10.1167/tvst.8.3.10. View

19.

Domenech-Estarellas E, Mamata H, Luo Z . Targeted steroid ointment application to the lid margins in ocular graft-versus-host disease associated blepharitis treatment. Ocul Surf. 2020; 21:348-350. DOI: 10.1016/j.jtos.2020.12.002. View

20.

Bradley J, Bradley R, McCartney D, Mannis M . Serum growth factor analysis in dry eye syndrome. Clin Exp Ophthalmol. 2009; 36(8):717-20. DOI: 10.1111/j.1442-9071.2008.01895.x. View